Abstract:The evolution of cancer treatment has provided increasingly targeted strategies both in the upfront and relapsed disease settings. Small‐molecule inhibitors and immunotherapy have risen to prominence with chimeric antigen receptor T‐cells, checkpoint inhibitors, kinase inhibitors, and monoclonal antibody therapies being deployed across a range of solid organ and haematological malignancies. However, novel approaches are required to target transcription factors and oncogenic fusion proteins that are central to cancer biology and have generally eluded successful drug development. Thalidomide analogues causing protein degradation have been a cornerstone of treatment in multiple myeloma, but a lack of in‐depth mechanistic understanding initially limited progress in the field. When the protein cereblon (CRBN) was found to mediate thalidomide analogues' action and CRBN's neo‐targets were identified, existing and novel drug development accelerated, with applications outside multiple myeloma, including non‐Hodgkin's lymphoma, myelodysplastic syndrome, and acute leukaemias. Critically, transcription factors were the first canonical targets described. In addition to broadening the application of protein‐degrading drugs, resistance mechanisms are being overcome and targeted protein degradation is widening the scope of druggable proteins against which existing approaches have been ineffective. Examples of targeted protein degraders include molecular glues and proteolysis targeting chimeras (PROTACs): heterobifunctional molecules that bind to proteins of interest and cause proximity‐induced ubiquitination and proteasomal degradation via a linked E3 ligase. Twenty years since their inception, PROTACs have begun progressing through clinical trials, with early success in targeting the oestrogen receptor and androgen receptor in breast and prostate cancer respectively. This review explores important developments in targeted protein degradation to both treat and study cancer. It also considers the potential advantages and challenges in the translational aspects of developing new treatments. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Targeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries

Molecular Glues For Targeted Protein Degradation: From Serendipity To Rational Discovery

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation

Molecular Glues Modulate Protein Functions by Inducing Protein Aggregation: A Promising Therapeutic Strategy of Small Molecules for Disease Treatment

Molecular glue degrader for tumor treatment

Molecular Glue Discovery: Current and Future Approaches.

Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity

Molecular glue degraders: exciting opportunities for novel drug discovery

Targeted protein degradation via intramolecular bivalent glues

Charged Molecular Glue Discovery Enabled by Targeted Degron Display

Emerging strategies for prospective discovery of molecular glue degraders

The emerging role of targeted protein degradation to treat and study cancer

Targeted protein degradation: from mechanisms to clinic

Targeted protein degradation: mechanisms, strategies and application

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Rational Design of Molecular Glues: Breakthroughs and Perspectives

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Crbn-based molecular Glues: Breakthroughs and perspectives

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery